Examkin

Soru

Zorluk: OrtaImmunizations and Vaccine-Preventable Diseases

A 15-month-old girl is brought to the clinic for a routine health maintenance visit. Her medical history is notable for a hospitalization at 11 months of age due to a 6-day history of high fever, bilateral nonexudative conjunctivitis, erythema of the oral mucosa, and a polymorphous rash. She was diagnosed with Kawasaki disease and treated successfully with high-dose intravenous immunoglobulin (IVIG) and aspirin. A follow-up echocardiogram performed last week showed normal coronary arteries. She is currently asymptomatic and takes no medications. Her last immunizations were administered at 6 months of age. Her vital signs and physical examination today are normal. Which of the following is the most appropriate approach to this patient's immunizations at this visit?

  1. Administer DTaP, Hib, and PCV vaccines today; defer MMR and varicella vaccines until 11 months after her IVIG infusionCevap
  2. B
    Administer DTaP, Hib, PCV, MMR, and varicella vaccines today
  3. C
    Administer DTaP, Hib, and PCV vaccines today; defer MMR and varicella vaccines until 6 months after her IVIG infusion
  4. D
    Administer MMR and varicella vaccines today; defer DTaP, Hib, and PCV vaccines until 11 months after her IVIG infusion
  5. E
    Defer all immunizations today and schedule them to be given 11 months after her IVIG infusion

Cevap

Administer DTaP, Hib, and PCV vaccines today; defer MMR and varicella vaccines until 11 months after her IVIG infusion
The correct approach is to administer inactivated vaccines on schedule and delay live-attenuated vaccines. High-dose IVIG contains a large pool of passively acquired antibodies that interfere with the replication of live-attenuated vaccine viruses (such as MMR and varicella), which is necessary to induce an adequate immune response. For the massive dose of IVIG used to treat Kawasaki disease (typically 2 g/kg), current guidelines require deferring these live vaccines for exactly 11 months. Conversely, passively acquired antibodies do not interfere with the immune response to inactivated vaccines, toxoids, or recombinant vaccines (e.g., DTaP, Hib, PCV). Therefore, these should be administered at the current visit to provide timely protection.

Adım Adım Çözüm

1
Identify the patient's past medical history and recent treatments.
The patient is a 15-month-old girl who received high-dose IVIG for Kawasaki disease at 11 months of age.
Recent administration of blood products or immunoglobulins heavily influences immunization schedules.
2
Determine the interaction between IVIG and vaccines.
IVIG provides passively acquired antibodies that neutralize live-attenuated virus vaccines (like MMR and varicella), but do not affect inactivated vaccines (like DTaP, Hib, and PCV).
Understanding which vaccine types are affected prevents administration of vaccines that will fail to produce immunity.
3
Calculate the required deferral interval for live vaccines based on the IVIG dose.
High-dose IVIG (2 g/kg) used for Kawasaki disease requires an 11-month delay before administering live-attenuated vaccines.
The duration of interference is directly proportional to the dose of immunoglobulin administered.
4
Formulate the immunization plan for today's visit.
Administer all catch-up inactivated vaccines today, but defer MMR and varicella until the child is 22 months old (11 months post-infusion).
This strategy maximizes protection against preventable diseases while ensuring the live vaccines will be fully effective when given.

Anahtar Kavram

High-dose intravenous immunoglobulin (IVIG) administration necessitates an 11-month deferral of live-attenuated vaccines (e.g., MMR, varicella) due to passive antibody interference. Inactivated vaccines can and should be administered on their normal schedule.
Bu soruyu puanla

Konular

Immunizations and Vaccine-Preventable Diseases

Bu konudan daha fazla soru